View Older Stories View More Recent Stories

Oct 21, 2020 07:01AM Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans
Oct 19, 2020 08:40AM Gilead (GILD) Presents New Data from Antiviral Development Programs at IDWeek 2020
Oct 19, 2020 08:30AM Gilead Presents New Data from Antiviral Development Programs at IDWeek 2020
Oct 16, 2020 07:29AM Gilead (GILD) Announces European CHMP Adopts Positive Opinion for Kite's KTE-X19 for the Treatment of R/R Mantle Cell Lymphoma
Oct 16, 2020 07:28AM European CHMP Adopts Positive Opinion for Kite’s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Oct 14, 2020 04:01PM Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020
Oct 14, 2020 08:33AM Gilead Sciences (GILD) Announces Expiration of HSR Waiting Period for Immunomedics (IMMU) Tender Offer
Oct 14, 2020 08:30AM Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for Immunomedics Tender Offer
Oct 8, 2020 05:15PM Gilead Sciences (GILD) Reports Final Results of NIAID ACTT-1 Trial Published in NEJM Expand Clinical Benefits of Veklury for Treatment of COVID-19
Oct 8, 2020 05:05PM Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment
Oct 5, 2020 06:27AM Gilead Sciences (GILD) Presents Biktarvy Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020
Oct 5, 2020 06:00AM Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020
Sep 30, 2020 08:38AM Gilead Sciences (GILD) Presents Data From HIV Research and Development Programs at HIV Glasgow 2020
Sep 30, 2020 08:37AM Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020
Sep 17, 2020 01:44PM Eli Lilly (LLY) Said Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19
Sep 15, 2020 08:01AM Gilead Sciences (GILD) Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome
Sep 15, 2020 08:00AM Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome
Sep 13, 2020 08:03PM Gilead Sciences (GILD) to Acquire Immunomedics (IMMU) for $21 Billion
Sep 13, 2020 03:00PM Gilead Sciences to Acquire Immunomedics
Sep 4, 2020 08:37AM Gilead's(GILD) Kite Submits sBLA to FDA for Yescarta in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas
Sep 4, 2020 08:30AM Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Yescarta® in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas
Aug 25, 2020 02:00AM Gilead Announces Presentation of More Than 40 Abstracts From Extensive Liver Disease Programs at the Digital International Liver Congress™ 2020
Aug 19, 2020 06:10AM Gilead Sciences (GILD) Receives CRL for Filgotinib for Treatment of Moderately to Severely Active Rheumatoid Arthritis
Aug 18, 2020 07:25PM Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
Aug 11, 2020 08:14AM Gilead Sciences (GILD) Announces China National Medical Products Administration Approves Truvada for HIV Pre-Exposure Prophylaxis
Aug 11, 2020 08:11AM China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)
Aug 10, 2020 11:00AM Gilead Sciences (GILD) Submits NDA to U.S. FDA for Veklury (Remdesivir) for Treatment of COVID-19
Aug 10, 2020 11:00AM Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19
Aug 7, 2020 08:00AM Pfizer (PFE) Announces Agreement with Gilead (GILD) to Manufacture Remdesivir for Treatment of COVID-19
Jul 30, 2020 04:02PM Gilead Sciences Announces Third Quarter 2020 Dividend
Jul 24, 2020 01:26PM Gilead Sciences (GILD) Kite Announced FDA Accelerated Approval of Tecartus to Treat MCL
Jul 24, 2020 01:25PM U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma
Jul 16, 2020 04:01PM Gilead Sciences to Release Second Quarter 2020 Financial Results on Thursday, July 30, 2020
Jul 10, 2020 08:31AM Gilead Sciences (GILD) Presents Additional Data on Remdesivir for Treatment of COVID-19
Jul 10, 2020 08:30AM Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
Jul 8, 2020 04:01AM Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders
Jul 4, 2020 03:01AM New Findings on Gilead’s Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults
Jul 4, 2020 03:01AM Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)
Jul 3, 2020 07:56AM European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COVID-19
Jul 1, 2020 08:30AM Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual
Jun 12, 2020 08:03AM Gilead Sciences (GILD) Company, Kite, Granted European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe
Jun 12, 2020 08:00AM Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe
Jun 4, 2020 01:10PM Chinese and Iranian hackers targeted Biden and Trump campaigns, Google says
Jun 1, 2020 04:05PM Mark Genovese Joins Gilead to Lead Clinical Development of Company’s Inflammation Programs
Jun 1, 2020 08:33AM Gilead Sciences (GILD) Remdesivir Moderate COVID-19 Study Shows 65% More Likely to have Clinical Improvement at Day 11
Jun 1, 2020 08:30AM Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
May 29, 2020 08:02AM Gilead Sciences (GILD) Announces Yescarta Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
May 29, 2020 08:02AM Gilead Sciences (GILD) Announces Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and AML
May 29, 2020 08:00AM Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia
May 29, 2020 08:00AM Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
View More Recent Stories View Older Stories